Advertisement

BioDrugs

, Volume 10, Issue 4, pp 257–264 | Cite as

Herpesvirus Vaccines

An Update
  • Roy Jennings
  • Tana Green
  • George R. Kinghorn
Leading Article

Abstract

The development of vaccines against the herpesviruses has major public health importance because of the wide spectrum of associated clinical disease with this virus in both immunocompetent and immunocompromised populations. Because these viruses establish latent infections capable of subsequent reactivation, both immunotherapeutic and prophylactic vaccine strategies are needed. A range of vaccine formulations has been devised, largely as a result of the rapid growth in knowledge in molecular microbiology and genetic engineering, including live and inactivated whole virus vaccines, and subunit vaccines consisting of recombinant viral glycoproteins in various adjuvants. The live attenuated virus Oka strain vaccine is now licensed for prophylaxis against varicella (VZV) in some countries.

Recent studies with herpes simplex viruses (HSV) have demonstrated immunogenicity with glycoprotein vaccines; however, these studies have also highlighted their failure to reduce seroconversion to HSV-2 in high-risk populations. Nevertheless, his work has helped develop comprehensive methodologies for the clinical amd immunological assessment of newer vaccine formulations which have proved successful in animal models. The live attenuated Towne strain vaccine has been shown to prevent severe human cytomegalovirus (CMV) infection in transplant recipients. More recently, subunit antigens and virus vector vaccines against CMV and Epstein Barr virus (EBV) have been devised. Novel attempts to present viral antigens now include the development of plasmid expression vectors for viral nucleic acids and genes as well as engineered live vectors for viral antigens. These new technologies may allow future vaccines to be devised, not only against the 5 well characterised herpes viruses, but also against the recently recognised herpes viruses 6, 7 and 8 whose full clinical spectrum is still unknown.

Keywords

Adis International Limited Epstein Barr Virus Genital Herpes Vaccine Formulation Varicella Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Roizman B. Herpesviridae: a brief introduction. In: Fields BN, Knipe DM, editors. Fields virology. New York: Raven Press 1990: 1787–93Google Scholar
  2. 2.
    Whitley RJ. Herpes simplex vaccines. In: Levine MM, Wood-row GC, Kaper JB, editors. New generation vaccines. New York: Mark Dekker Inc., 1997: 727–47Google Scholar
  3. 3.
    Rinaldo CR, Torpey DJ III. Cell-mediated immunity and immunosuppression in herpes simplex virus infection. Immunodeficiency 1993; 5: 33–90PubMedGoogle Scholar
  4. 4.
    Jennings R, NíChallináin D, Ghazi HO, et al. Vaccines and vaccine delivery systems: experience with HSV, influenza and mucosal routes of immunisation. In: Gregoriadis G, editor. Vaccine design: the role of cytokine networks. New York: Plenum Press, 1997: 119–27Google Scholar
  5. 5.
    Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal, but not systemic immunisation. J Exp Med 1996; 184: 1879–90PubMedCrossRefGoogle Scholar
  6. 6.
    Plotkin S. Vaccines for varicella-zoster virus and cytomegalo-virus: recent progress. Science 1994; 265: 1383–5PubMedCrossRefGoogle Scholar
  7. 7.
    Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; II: 1288–90CrossRefGoogle Scholar
  8. 8.
    Asano Y, Suga S, Yoshikama T, et al. Experience and reason; twenty year follow up of protective immunity of the Oka live varicella vaccine. Paediatrics 1994; 94: 524–6Google Scholar
  9. 9.
    Holmes SJ. Review of recommendations of the advisory committee on immunisation practices, centers for the disease control and prevention on varicella vaccine. J Infect Dis 1996; 174Suppl.3: S342–4PubMedCrossRefGoogle Scholar
  10. 10.
    Stanberry LR. Herpes immunisation - on the threshold. J Eur Acad Dermatol Venereol 1996; 7: 120–8Google Scholar
  11. 11.
    De Maria A, Tundo P, Romano A, et al. Anti-HSV-1 herpes vaccination by Lupidon H: preliminary results. Adv Exp Biol Med 1995; 371B: 1599–600Google Scholar
  12. 12.
    Cadoz M, Micoud M, Seigneurin JM, et al. Phase I trial of R7020: A live attenuated recombinant herpes simplex (HSV) candidate vaccine. Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14; Anaheim, CA, USAGoogle Scholar
  13. 13.
    Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994; 343: 1460–3PubMedCrossRefGoogle Scholar
  14. 14.
    Langenberg AGM, Burke RL, Adair SF. Recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann Intern Med 1995; 122: 889–98PubMedGoogle Scholar
  15. 15.
    Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176: 1129–34PubMedCrossRefGoogle Scholar
  16. 16.
    Byars NE, Fraser-Smith EB, Pecyk RA, et al. Vaccinating guinea-pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 1994; 12: 200–9PubMedCrossRefGoogle Scholar
  17. 17.
    Burke RL, Goldbeck C, Ng P, et al. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 1994; 170: 1110–9PubMedCrossRefGoogle Scholar
  18. 18.
    Ghiasi H, Nesburn AB, Wechsler SL. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine 1996; 14: 107–12PubMedCrossRefGoogle Scholar
  19. 19.
    Straus SE, Savarese B, Tigges M, et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis 1993; 167: 1045–52PubMedCrossRefGoogle Scholar
  20. 20.
    Zheng B, Graham FL, Johnson DC, et al. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 1993; 11: 1191–8PubMedCrossRefGoogle Scholar
  21. 21.
    Gallichan WS, Rosenthal KL. Specific secretory immune responses in the female genital tract following intranasal immunisation with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995; 13: 1589–95PubMedCrossRefGoogle Scholar
  22. 22.
    Heineman TC, Connelly BL, Bourne N, et al. Immunisation with recombinant varicella zoster virus expressing herpes simplex type 2 glycoprotein D reduces the severity of genital herpes in guinea-pigs. J Virol 1996; 69: 8109–13Google Scholar
  23. 23.
    Karem KL, Bowen J, Kuklin L, et al. Protective immunity against herpes simplex (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 1997; 78: 427–34PubMedGoogle Scholar
  24. 24.
    Bourne N, Milligan GN, Schleiss MR, et al. DNA immunisation confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996; 14: 1230–4PubMedCrossRefGoogle Scholar
  25. 25.
    McClements WL, Armstrong ME, Keys RD, et al. The prophylactic effect of immunisation with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea-pigs. Vaccine 1997; 15: 857–60PubMedCrossRefGoogle Scholar
  26. 26.
    Kuklin N, Daheshia M, Karem K, et al. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunisation. J Virol 1997; 71: 3138–45PubMedGoogle Scholar
  27. 27.
    Nakao M, Hazama M, Mayumi-Aono A, et al. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. J Infect Dis 1994; 169: 787–91PubMedCrossRefGoogle Scholar
  28. 28.
    Morrison LA, Knipe DM. Immunisation with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994; 68: 689–96PubMedGoogle Scholar
  29. 29.
    McLean CS, Erturk M, Jennings R, et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994; 170: 1100–9PubMedCrossRefGoogle Scholar
  30. 30.
    Bournsell MEG, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997; 175: 16–25CrossRefGoogle Scholar
  31. 31.
    Walker J, Leib DA. Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine 1998; 16: 1–5PubMedCrossRefGoogle Scholar
  32. 32.
    Brehm MA, Bonneau RH, Knipe DM, et al. Immunisation with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1. J Virol 1997; 71: 3534–44PubMedGoogle Scholar
  33. 33.
    Dacosta XJ, Bourne N, Stanberry LR, et al. Construction and characterisation of a replication defective herpes simplex virus 2 ICP8 mutant strain and its use in immunisation studies in a guinea-pig model of genital disease. Virology 1997; 232: 1–12CrossRefGoogle Scholar
  34. 34.
    Ho RJY, Burke RL, Merigan TC. Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD. Vaccine 1994; 12: 235–42PubMedCrossRefGoogle Scholar
  35. 35.
    Garcia-Valcarcel M, Fowler WJ, Harper DR, et al. Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus like particles carrying fragments of glycoprotein E(gE). Vaccine 1997; 15: 709–19PubMedCrossRefGoogle Scholar
  36. 36.
    Gonczol E, Berensci K, Pincus S, et al. Preclinical evaluation of an ALVAC(canarypox)-humancytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995; 13: 1080–5PubMedCrossRefGoogle Scholar
  37. 37.
    Gu SY, Huang TM, Ryan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Standardisation 1995; 84: 171–7Google Scholar
  38. 38.
    Walker RI. New strategies for using mucosal immunisation to achieve more effective immunisation. Vaccine 1994; 387–400Google Scholar
  39. 39.
    McLean CS, NíChallanáin D, Duncan I, et al. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine 1996; 14: 987–92PubMedCrossRefGoogle Scholar
  40. 40.
    Delves PJ, Lund T, Roitt IM. Can epitope-focused vaccines select advantageous immune responses? Mol Med Today 1997; 3: 55–60PubMedCrossRefGoogle Scholar
  41. 41.
    Irie H, Harada Y, Kataoka M, et al. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine. J Virol 1992; 66: 2428–34PubMedGoogle Scholar
  42. 42.
    McKenzie R, Straus SE. Vaccine therapy for herpes simplex virus infections. Rev Med Virol 1996; 6: 85–96PubMedCrossRefGoogle Scholar
  43. 43.
    Levin MJ, Hayward AR. The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am 1996; 10: 657–75PubMedCrossRefGoogle Scholar
  44. 44.
    Gershon AA, La Russa P, Steinberg S, et al. The protective effect of immunologic boosting against zoster: an analysis in leukaemic children who were vaccinated against chickenpox. J Infect Dis 1996; 173: 450–3PubMedCrossRefGoogle Scholar
  45. 45.
    Hayward AR, Buda K, Levin MJ. Immune response to secondary immunisation with live or inactivated VZV vaccine in elderly adults. Viral Immunol 1994; 7: 31–6PubMedCrossRefGoogle Scholar
  46. 46.
    Lowhagen G, Jansen E, Nordenfelt E, et al. Epidemiology of genital infections in Sweden. Acta Derm Venereol 1990; 70: 330–4PubMedGoogle Scholar
  47. 47.
    Kinghorn GR. Anogenital herpes. Venereology 1995; 8: 223–9Google Scholar
  48. 48.
    Kinghorn GR. Limiting the spread of genital herpes. Scand J Infect Dis Suppl 1996; 100: 20–5PubMedGoogle Scholar
  49. 49.
    Hook III EW, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992; 165: 251–5PubMedCrossRefGoogle Scholar
  50. 50.
    S Straus HSV Vaccines. Clinical trial results and future prospects [abstract]. 5th Annual Meeting, International Herpes Management Forum; 1997 Nov 22–25, Cannes, France: 7Google Scholar
  51. 51.
    Grose C. Pathogenesis of infection with varicella vaccine. Infect Dis Clin North Am 1996; 10: 489–505PubMedCrossRefGoogle Scholar
  52. 52.
    Gershon AA, La Russa P, Hardy I, et al. Varicella vaccine: the American experience. J Infect Dis 1992; 166Suppl. 1: S63–8PubMedCrossRefGoogle Scholar
  53. 53.
    Arvin AM, Gershon AA. Live attenuated varicella vaccine. Annu Rev Microbiol 1996; 50: 59–100PubMedCrossRefGoogle Scholar
  54. 54.
    Watson R, Gupta R, Randall T, et al. Persistence of cell mediated and humoral immune responses in healthy children immunised with live attenuated varicella vaccine. J Infect Dis 1994; 169: 197–9PubMedCrossRefGoogle Scholar
  55. 55.
    Watson BM, Lanfer DS, Kuter BJ, et al. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine (MMRII V) in healthy children. J Infect Dis 1996; 173: 731–4PubMedCrossRefGoogle Scholar
  56. 56.
    White CJ, Stinson D, Staehle B, et al. Measles, mumps, rubella and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, mumps, rubella, varicella vaccine study group. Clin Infect Dis 1997; 24: 925–31PubMedCrossRefGoogle Scholar
  57. 57.
    Yow MD, Demmler GJ. Congenital cytomegalovirus disease - 20 years is long enough. N Engl J Med 1992; 326: 702–3PubMedCrossRefGoogle Scholar
  58. 58.
    Plotkin SA, Furukawa T, Zygraich N, et al. Candidate cytomegalovirus strain for human vaccination. Infect Immun 1975; 12: 521–7PubMedGoogle Scholar
  59. 59.
    Glazer JP, Friedman HM, Grossman RA, et al. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Ann Intern Med 1979; 91: 676–83PubMedGoogle Scholar
  60. 60.
    Marker SC, Simmons RL, Balfour Jnr HH. Cytomegalovirus vaccine in renal allograft recipients. Transplant Proc 1981; 13: 117–9PubMedGoogle Scholar
  61. 61.
    Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991; 124: 525–31Google Scholar
  62. 62.
    Plotkin SA, Higgins R, Kurtz JB, et al. Multicentre trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58: 1176–8PubMedGoogle Scholar
  63. 63.
    Plotkin SA, Huang E-S. Cytomegalovirus vaccine virus (Towne Strain) does not induce latency. J Infect Dis 1985; 152: 395–7PubMedCrossRefGoogle Scholar
  64. 64.
    He H, Rinaldo CR Jr, Morel PA. T-cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development. J Gen Virol 1995; 76: 1603–10PubMedCrossRefGoogle Scholar
  65. 65.
    Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunisation with human cytomegalovirus vaccine. J Infect Dis 1996; 174: 387–92PubMedCrossRefGoogle Scholar
  66. 66.
    Berenssi K, Gonczol E, Endresz V, et al. The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response. Vaccine 1996; 14: 369–74CrossRefGoogle Scholar
  67. 67.
    Moss DJ, Burrows, SR, Suhrbier A, et al. Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response. Ciba Found Symp 1994; 187: 4–13PubMedGoogle Scholar
  68. 68.
    Rickinson AB. Immune intervention against virus-associated human cancers. Ann Oncol 1995; 6Suppl. 1: 69–71PubMedGoogle Scholar
  69. 69.
    Donnelly JJ, Ulmer JB, Shiver JW, et al. DNA vaccines. Annu Rev Immunol 1997; 15: 617–48PubMedCrossRefGoogle Scholar
  70. 70.
    Lowry PW, Koropchak CM, Choi CY, et al. The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (1E62) expressed in recombinant herpes simplex virus-1. Antiviral Res 1997; 33: 187–200PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Roy Jennings
    • 1
  • Tana Green
    • 2
  • George R. Kinghorn
    • 2
  1. 1.Division of Molecular and Genetic Medicine and Sheffield Institute for Vaccine StudiesUniversity of Sheffield Medical SchoolSheffieldEngland
  2. 2.Department of Genitourinary MedicineRoyal Hallamshire HospitalSheffieldEngland

Personalised recommendations